News | Mammography | January 12, 2021

This cutting-edge technology assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately

This cutting-edge technology assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately

January 12, 2021 — Therapixel announced that MammoScreen has successfully obtained the CE mark. After having received FDA clearance for commercial sales in the United States in March 2020, this artificial intelligence (AI) solution is now available in the European market.

MammoScreen automatically analyzes screening mammograms and indicates suspicious mammograms and lesions to the radiologist. According to the probability of malignancy and the degree of confidence of the algorithm, the software assigns a unique "MammoScreen Score" ranging from 1 to 10.

A clinical study conducted in 2019 and published in Radiology: AI, showed that radiologists assisted by MammoScreen have a better performance than without the software.

MammoScreen helps to increase the interpretation speed of benign images, giving readers more time to focus on cases requiring more attention.

Already installed in 14 hospitals and radiology practices in France for clinical evaluations, MammoScreen has generated a lot of enthusiasm among radiologists. Physicians perceive it as an intuitive and easy-to-use tool that helps reassure themselves in the interpretation and avoid missing cancers.

Breast cancer is one of the most common and deadliest cancers in women worldwide, affecting 1 in 8 women in their lifetime. The earlier this disease is diagnosed, the more effective the treatment is.

"We are proud to have received the CE Mark. This brings us a step closer to our goal of reducing breast cancer burden worldwide by improving breast cancer screening," said Pierre Fillard, Therapixel's Founder and Chief Scientific Officer.

"I am confident that MammoScreen will not only increase radiologists' performance but will also improve the patient experience by reassuring women faster," stated Matthieu Leclerc-Chalvet, CEO of Therapixel.

For more information: www.mammoscreen.com


Related Content

News | Prostate Cancer

July 9, 2025 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer ...

Time July 09, 2025
arrow
News | Breast Imaging

July 8, 2025 — QT Imaging Holdings, has appointed Elaine Iuanow, MD, as chief medical officer (CMO) and Kim Du as senior ...

Time July 09, 2025
arrow
News | Breast Imaging

July 7, 2025 — SimonMed Imaging, one of the largest outpatient medical imaging providers in the United States, has ...

Time July 08, 2025
arrow
News | Magnetic Resonance Imaging (MRI)

July 2, 2025 — Philips has received FDA 510(k) clearance for SmartSpeed Precise[1] MR’s latest deep learning ...

Time July 03, 2025
arrow
News | Ultrasound Imaging

July 1, 2025 — UPDATE: The final paper is now available at: JMIR AI - ChatGPT-4–Driven Liver Ultrasound Radiomics ...

Time July 01, 2025
arrow
News | Magnetic Resonance Imaging (MRI)

June 26, 2025 — Siemens Healthineers has received Food and Drug Administration clearance for the Magnetom Flow.Ace, its ...

Time June 26, 2025
arrow
News | Prostate Cancer

June 26, 2025 – Quibim, a global provider of quantitative medical imaging solutions, has launched AI-QUAL, a new feature ...

Time June 26, 2025
arrow
News | Breast Imaging

June 25, 2025 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time June 25, 2025
arrow
News | Women's Health

June 23, 2025 — Susan G. Komen, the world’s leading breast cancer organization, recently announced it is awarding $10.8 ...

Time June 23, 2025
arrow
News | Bone Densitometry Systems

June 19, 2025 — Naitive Technologies has published results demonstrating the diagnostic performance of its AI-powered ...

Time June 18, 2025
arrow
Subscribe Now